{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:45:20Z","timestamp":1761864320890,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a population of 42 Philadelphia negative myeloproliferative neoplasm patients, all on systemic active treatment, the likelihood of responding to anti-SARS-CoV-2 BNT162b2 vaccine at 2\u00a0weeks after the second dose was significantly lower in the ten patients with myelofibrosis compared to the 32 with essential thrombocythemia (<jats:italic>n<\/jats:italic>\u2009=\u200917) and polycythemia vera (<jats:italic>n<\/jats:italic>\u2009=\u200915) grouped together, both in terms of neutralizing anti-SARS-CoV-2 IgG titers and seroprotection rates (32.47\u00a0AU\/mL vs 217.97\u00a0AU\/mL, <jats:italic>p<\/jats:italic>\u2009=\u20090.003 and 60% vs 93.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.021, respectively). Ruxolitinib, which was the ongoing treatment in five patients with myelofibrosis and three with polycythemia vera, may be implicated in reducing vaccine immunogenicity (<jats:italic>p<\/jats:italic>\u2009=\u20090.076), though large prospective study is needed to address this issue.<\/jats:p>","DOI":"10.1186\/s13045-021-01130-1","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T12:04:02Z","timestamp":1627560242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia"],"prefix":"10.1186","volume":"14","author":[{"given":"Fulvia","family":"Pimpinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-2272","authenticated-orcid":false,"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Falcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Spadea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pontone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Laquintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"La Malfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enea Gino","family":"Di Domenico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Di Bella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Falzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Ensoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branka","family":"Vujovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"1130_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","volume":"14","author":"F Pimpinelli","year":"2021","unstructured":"Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week-immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single Institution. J Hematol Oncol. 2021;14:81. https:\/\/doi.org\/10.1186\/s13045-021-01090-6.","journal-title":"J Hematol Oncol"},{"key":"1130_CR2","unstructured":"https:\/\/www.diasorin.com\/en\/immunodiagnostic-solutions\/clinical-areas\/infectious-diseases\/covid-19."},{"key":"1130_CR3","doi-asserted-by":"publisher","first-page":"e01224","DOI":"10.1128\/JCM.01224-20","volume":"58","author":"F Bonelli","year":"2020","unstructured":"Bonelli F, Sarasini A, Zierold C, Calleri M, Bonetti A, Vismara C, et al. Clinical and analytical performance of an automated serological test that identifies S1\/S2-neutralizing IgG in COVID-19 patients semiquantitatively. J Clin Microbiol. 2020;58:e01224-e1320.","journal-title":"J Clin Microbiol"},{"key":"1130_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","volume":"35","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35:485\u201393.","journal-title":"Leukemia"},{"key":"1130_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01070-8","author":"B Kamaz","year":"2020","unstructured":"Kamaz B, Mullally A. COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia. 2020. https:\/\/doi.org\/10.1038\/s41375-020-01070-8.","journal-title":"Leukemia"},{"key":"1130_CR6","doi-asserted-by":"publisher","first-page":"100755","DOI":"10.1016\/j.cegh.2021.100755","volume":"11","author":"I Wijaya","year":"2021","unstructured":"Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, et al. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis. Clin Clin Epidemiol Glob Health. 2021;11:100755. https:\/\/doi.org\/10.1016\/j.cegh.2021.100755.","journal-title":"Clin Clin Epidemiol Glob Health"},{"issue":"5","key":"1130_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002392","volume":"9","author":"L Iovino","year":"2021","unstructured":"Iovino L, Thur LA, Gnjatic S, Chapuis A, Milano F, Hill JA. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. J Immunother Cancer. 2021;9(5): e002392. https:\/\/doi.org\/10.1136\/jitc-2021-002392.","journal-title":"J Immunother Cancer"},{"key":"1130_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01300-7","volume":"22","author":"P Harrington","year":"2021","unstructured":"Harrington P, de Lavallade H, Doores KJ, O\u2019Reilly A, Seow J, Graham C, et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralizing antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia. 2021;22:1\u20135. https:\/\/doi.org\/10.1038\/s41375-021-01300-7.","journal-title":"Leukemia"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01130-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T12:15:43Z","timestamp":1627560943000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01130-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01130-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"type":"electronic","value":"1756-8722"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study was formally approved by the Ethical Committee of IRCCS Central Ethical Committee of Regione Lazio in January 2021 (Prot. N-1463\/21). The study was conducted in compliance with Helsinki declaration and Good Clinical Practice, and all subjects signed a specific written informed consent before study enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}